Development of Nanoemulsions for Topical Application of Mupirocin

Mupirocin (MUP) is a topical antibacterial agent used to treat superficial skin infections but has limited application due to in vivo inactivation and plasma protein binding. A nanoemulsion formulation has the potential to enhance the delivery of mupirocin into the skin. MUP-loaded nanoemulsions wer...

Full description

Saved in:
Bibliographic Details
Main Authors: Bahjat Alhasso (Author), Muhammad Usman Ghori (Author), Barbara R. Conway (Author)
Format: Book
Published: MDPI AG, 2023-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2ee08d4e0b84437a852cf3c65f69b3a1
042 |a dc 
100 1 0 |a Bahjat Alhasso  |e author 
700 1 0 |a Muhammad Usman Ghori  |e author 
700 1 0 |a Barbara R. Conway  |e author 
245 0 0 |a Development of Nanoemulsions for Topical Application of Mupirocin 
260 |b MDPI AG,   |c 2023-01-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15020378 
500 |a 1999-4923 
520 |a Mupirocin (MUP) is a topical antibacterial agent used to treat superficial skin infections but has limited application due to in vivo inactivation and plasma protein binding. A nanoemulsion formulation has the potential to enhance the delivery of mupirocin into the skin. MUP-loaded nanoemulsions were prepared using eucalyptus oil (EO) or eucalyptol (EU), Tween<sup>®</sup> 80 (T80) and Span<sup>®</sup> 80 (S80) as oil phase (O), surfactant (S) and cosurfactant (CoS). The nanoemulsions were characterised and their potential to enhance delivery was assessed using an in vitro skin model. Optimised nanoemulsion formulations were prepared based on EO (MUP-NE EO) and EU (MUP-NE EU) separately. MUP-NE EO had a smaller size with mean droplet diameter of 35.89 ± 0.68 nm and narrower particle size index (PDI) 0.10 ± 0.02 nm compared to MUP-NE EU. Both nanoemulsion formulations were stable at 25 °C for three months with the ability to enhance the transdermal permeation of MUP as compared to the control, Bactroban<sup>®</sup> cream. Inclusion of EU led to a two-fold increase in permeation of MUP compared to the control, while EO increased the percentage by 48% compared to the control. Additionally, more MUP was detected in the skin after 8 h following MUP-NE EU application, although MUP deposition from MUP-NE EO was higher after 24 h. It may be possible, through choice of essential oil to design nanoformulations for both acute and prophylactic management of topical infections. 
546 |a EN 
690 |a eucalyptus oil 
690 |a eucalyptol 
690 |a mupirocin 
690 |a nanoemulsion 
690 |a topical delivery 
690 |a permeation 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 2, p 378 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/2/378 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/2ee08d4e0b84437a852cf3c65f69b3a1  |z Connect to this object online.